Maravai LifeSciences (NASDAQ:MRVI) Announces Earnings Results, Beats Estimates By $0.02 EPS

Posted by Brenda Bartman on Aug 8th, 2026

Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02, FiscalAI reports. Maravai LifeSciences had a negative net margin of 37.07% and a negative return on equity of 15.34%. The company had revenue of $51.44 million during the quarter, compared to analysts’ expectations of $48.67 million.

Here are the key takeaways from Maravai LifeSciences’ conference call:

Q2 revenue grew 9% year over year to $51.4 million, led by 12% growth at TriLink, including a 55% increase in GMP consumables and 17% growth in discovery mRNA. Cygnus also delivered its fifth consecutive quarter of growth, with revenue up 3%.
Profitability improved sharply, with adjusted gross margin expanding more than 1,600 basis points to 58.9% and adjusted EBITDA rising $19.1 million year over year to $8.7 million. Management attributed the improvement to higher revenue, favorable mix and cost restructuring.
Maravai significantly strengthened its balance sheet by refinancing debt, ending the quarter with $147.1 million of debt and $70.1 million of cash, while extending maturities to 2032. Management said debt has been cut roughly in half since the start of 2026, improving financial flexibility.
The company raised full-year adjusted EBITDA guidance to $33 million-$35 million and now expects gross-margin improvement of more than 1,400 basis points, while maintaining 2026 revenue guidance of $205 million-$215 million. Management cited strong demand but kept revenue guidance prudent because CDMO and large GMP orders are program-driven and can shift between quarters.
Innovation and pipeline adoption continued to build: ModTail exceeded 125 customers one year after launch, GMP-grade ModTail is expected to launch later in 2026 with customer orders anticipated in 2027, and TriLink now has six GMP customers transitioning in 2026. Longer-term commercial-program growth is expected to become more meaningful around 2027-2029, but timing remains dependent on customers’ clinical progress.

Maravai LifeSciences Stock Performance

Shares of MRVI traded down $0.02 on Friday, reaching $6.23. The company’s stock had a trading volume of 4,077,168 shares, compared to its average volume of 2,684,640. The stock’s 50 day simple moving average is $5.98 and its two-hundred day simple moving average is $4.38. The company has a debt-to-equity ratio of 0.72, a current ratio of 5.91 and a quick ratio of 4.96. The stock has a market capitalization of $1.61 billion, a P/E ratio of -11.98 and a beta of 0.63. Maravai LifeSciences has a 12-month low of $2.03 and a 12-month high of $7.44.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Weiss Ratings upgraded Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 29th. Wells Fargo & Company lifted their price target on Maravai LifeSciences from $5.50 to $6.50 and gave the stock an “overweight” rating in a research report on Friday. UBS Group reaffirmed a “reduce” rating on shares of Maravai LifeSciences in a report on Wednesday, June 3rd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $6.00 price target on shares of Maravai LifeSciences in a research report on Friday, May 8th. Finally, Wall Street Zen lowered shares of Maravai LifeSciences from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Three research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $5.83.

Check Out Our Latest Stock Report on MRVI

Insider Activity

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the company’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total value of $126,500.00. Following the completion of the sale, the general counsel directly owned 360,767 shares in the company, valued at $1,825,481.02. This represents a 6.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.49% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Maravai LifeSciences

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC lifted its stake in shares of Maravai LifeSciences by 3.0% in the 4th quarter. Barclays PLC now owns 172,281 shares of the company’s stock valued at $560,000 after purchasing an additional 5,057 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Maravai LifeSciences by 12.5% in the second quarter. The Manufacturers Life Insurance Company now owns 46,528 shares of the company’s stock valued at $112,000 after buying an additional 5,160 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in Maravai LifeSciences by 121.1% in the second quarter. Tower Research Capital LLC TRC now owns 18,021 shares of the company’s stock valued at $43,000 after buying an additional 9,870 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Maravai LifeSciences in the fourth quarter worth about $34,000. Finally, Insigneo Advisory Services LLC acquired a new stake in shares of Maravai LifeSciences during the 4th quarter valued at about $34,000. 50.25% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Maravai LifeSciences

Here are the key news stories impacting Maravai LifeSciences this week:

Positive Sentiment: Maravai reported second-quarter revenue of $51.44 million, exceeding analysts’ $48.67 million consensus estimate. The company also reported a quarterly loss per share of approximately $0.02, narrower than expectations of roughly $0.04-$0.05, according to the earnings coverage. Maravai LifeSciences Reports Second Quarter 2026 Financial Results
Positive Sentiment: Wells Fargo’s higher valuation target and “Overweight” rating indicate greater confidence in Maravai’s growth outlook and provide a near-term catalyst for the shares. Wells Fargo price target report
Neutral Sentiment: Management issued fiscal 2026 revenue guidance of $205 million to $215 million, a range that broadly brackets the $210.4 million analyst consensus. The update offers limited surprise but provides visibility into the company’s expected performance. Maravai LifeSciences 2026 Q2 Results Presentation
Negative Sentiment: Maravai remains unprofitable, with a negative net margin and negative return on equity. Continued quarterly losses could limit the stock’s upside unless revenue growth translates into improving profitability. Maravai LifeSciences Q2 earnings coverage

About Maravai LifeSciences

(Get Free Report)

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.